ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
April 01, 2025

Extension of Warrants in Incanthera to 30 September 2025

Read More
March 14, 2025

ImmuPharma Attending Bio-Europe Spring – 17-19 March 2025, Milan

Read More
March 13, 2025

ImmuPharma proves unique Mechanism of Action of P140

Read More
February 22, 2025

TR1 from Lanstead – Major interest in shares

Read More
February 13, 2025

Lanstead Subscription & Oversubscribed Placing to ‘c.£2.91 million | Sharing Agreement | Related Party Transactions

Read More
January 28, 2025

Response to Share Price Movement

Read More
January 09, 2025

ImmuPharma Announces Breakthrough Findings into Autoimmune Diseases

Read More
January 08, 2025

Immupharma at JP MORGAN CONFERENCE and BIOTECH SHOWCASE 11-16 January 2025, San Francisco

Read More
December 24, 2024

Change of Auditor

Read More
December 04, 2024

Appointment of Company Secretary

Read More
October 11, 2024

Notification of Major Holding – Lanstead Capital

Read More
September 11, 2024

Extension of Warrants in Incanthera to 31 March 2025

Read More
  • 1
  • 2
  • 3
  • …
  • 23
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved